Skip to content

Platform
- Overview
- Publications
Pipeline
Patients
About Us
Partnerships
News
Careers

Platform
- Overview
- Publications
Pipeline
Patients
About Us
Partnerships
News
Careers

MM+M: Cour Pharmaceuticals CEO John Puisis discusses $105M funding round

By lsc-webmaster / February 16, 2024

Myasthenia Gravis News: $105M raised to support clinical trial of CNP-106 in gMG patients

COUR Pharmaceuticals Appoints Paul M. Peloso, MD, as Chief Medical Officer

Skokie, Illinois
info@courpharma.com

Science

Platform
Publications
Pipeline

Patients

Overview
Patient Resources
CNP-103 Clinical Trial in Type 1 Diabetes
CNP-106 Clinical Trial in Myasthenia Gravis

Company

About Us
Partnerships
News
Careers

Privacy Policy
Terms of use
Accessibility
Expanded Access Policy
Cookie policy

© 2025 COUR Pharmaceuticals

Scroll to Top